Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Abroad (travel likely)RecruitingPHASE2

Conditions

Locally Recurrent Rectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Zhen Zhang, M.D, PH.D) · zhen_zhang@fudan.edu.cn · 19521280960

Study leads

Zhen Zhang, MD, PhD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Locally Recurrent Rectal Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Recurrent Rectal Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Solid Tumor, Adult · Colorectal Cancer · NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · La Jolla, United States

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

Unresectable Locally Recurrent Rectal Cancer

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China